Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionNissay Asset Management Corp /japan/ /adv
Latest Disclosed Ownership12,595 shares
Latest Disclosed Value $ 1,659,265
Nissay Asset Management Corp /japan/ /adv reports 1.64% increase in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 15, 2026 - Nissay Asset Management Corp /japan/ /adv filed a 13F-HR form disclosing ownership of 12,595 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $1,659,265 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 12,392 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 1.64% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 12,595 203 1.64 1,659 -5.58 0.0088
2026-02-17 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 12,392 76 0.62 1,758 1.68 0.0091
2025-11-14 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 12,316 66 0.54 1,729 12.28 0.0095
2025-08-14 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 12,250 -43 -0.35 1,540 13.25 0.0090
2025-05-15 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 12,293 107 0.88 1,360 -20.01 0.0088
2025-02-14 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 12,186 146 1.21 1,699 22.49 0.0104
2024-11-14 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 12,040 466 4.03 1,387 -12.93 0.0088
2024-08-14 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 11,574 401 3.59 1,593 3.44 0.0105
2024-05-15 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 11,173 233 2.13 1,541 6.87 0.0107
2024-02-14 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 10,940 354 3.34 1,441 21.09 0.0116
2023-11-14 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 10,586 354 3.46 1,191 23.44 0.0106
2023-08-14 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 10,232 -191 -1.83 965 -8.63 0.0083
2023-05-15 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 10,423 -402 -3.71 1,055 -18.34 0.0094
2023-02-14 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 10,825 -237 -2.14 1,293 9.96 0.0124
2022-11-14 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 11,062 431 4.05 1,175 13.42 0.0123
2022-08-15 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 10,631 -130 -1.21 1,036 2.68 0.0103
2022-05-16 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 10,761 265 2.52 1,009 12.86 0.0088
2022-02-14 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 10,496 419 4.16 894 -7.45 0.0068
2021-11-10 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 10,077 409 4.23 966 2.66 0.0082
2021-08-13 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 9,668 440 4.77 941 4.91 0.0083
2021-05-11 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 9,228 -222 -2.35 897 -0.99 0.0088
2021-02-08 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 9,450 358 3.94 906 3.66 0.0136
2020-10-20 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 9,092 237 2.68 874 -19.07 0.0148
2020-07-27 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 8,855 1,159 15.06 1,080 62.16 0.0210
2020-05-05 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,696 318 4.31 666 -16.02 0.0170
2020-02-14 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,378 7,378 793 0.0176
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.